Arrowhead Pharmaceuticals Inc

CFO Daniel Apel Executes Strategic Sell‑Off of 21,155 Arrowhead Shares at $70.45, Locking in Gains Amid Strong 446% YTD Return

Arrowhead CFO Daniel Apel’s strategic April 2026 sales reveal disciplined insider trading—no panic, just a planned divestiture that keeps investor confidence high.

Arrowhead Pharmaceuticals Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

25/04/2026, 01:00

3 minutes to read

Arrowhead CMO’s Zero‑Price Buy Signals Insider Confidence Amid Pipeline Boom and Capital Raise

Arrowhead’s CMO flips from selling to buying, buying 75,000 shares at a zero‑price entry, signaling renewed confidence in its RNAi obesity pipeline and upcoming capital raise.

Arrowhead Pharmaceuticals Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

09/01/2026, 01:01

3 minutes to read